IDEXX CEO exercises options, sells 23K shares
IDEXX Laboratories President and CEO Jonathan Jay Mazelsky exercised stock options for 23,523 shares of common stock at exercise prices of $141.6000 and $505.5300.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
IDEXX Laboratories President and CEO Jonathan Jay Mazelsky exercised stock options for 23,523 shares of common stock at exercise prices of $141.6000 and $505.5300. He then sold 23,326 shares in multiple open-market trades at prices including $650.6695 and $663.0439, ending with 83,803.302 shares held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option (right-to-buy) | 197 | $0.00 | $0.00 |
| Exercise | Common Stock | 197 | $505.53 | $100K |
| Exercise | Non-Qualified Stock Option (right-to-buy) | 23,326 | $0.00 | $0.00 |
| Exercise | Common Stock | 23,326 | $141.60 | $3.30M |
| Sale | Common Stock | 1,281 | $650.6695 | $834K |
| Sale | Common Stock | 1,095 | $651.4866 | $713K |
| Sale | Common Stock | 1,669 | $652.4945 | $1.09M |
| Sale | Common Stock | 1,171 | $653.6763 | $765K |
| Sale | Common Stock | 1,111 | $654.6294 | $727K |
| Sale | Common Stock | 1,488 | $655.8498 | $976K |
| Sale | Common Stock | 1,343 | $656.8451 | $882K |
| Sale | Common Stock | 2,860 | $657.8438 | $1.88M |
| Sale | Common Stock | 3,660 | $658.9166 | $2.41M |
| Sale | Common Stock | 2,859 | $659.7495 | $1.89M |
| Sale | Common Stock | 1,200 | $661.0976 | $793K |
| Sale | Common Stock | 1,000 | $662.1567 | $662K |
| Sale | Common Stock | 2,589 | $663.0439 | $1.72M |
Footnotes (15)
- F1. Represents the weighted average price of the shares sold ranging from a low of $650.00 to a high of $650.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F2. Represents the weighted average price of the shares sold ranging from a low of $651.06 to a high of $651.85 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F3. Represents the weighted average price of the shares sold ranging from a low of $652.105 to a high of $653.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F4. Represents the weighted average price of the shares sold ranging from a low of $653.19 to a high of $654.155 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F5. Represents the weighted average price of the shares sold ranging from a low of $654.24 to a high of $655.2175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F6. Represents the weighted average price of the shares sold ranging from a low of $655.275 to a high of $656.205 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F7. Represents the weighted average price of the shares sold ranging from a low of $656.28 to a high of $657.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F8. Represents the weighted average price of the shares sold ranging from a low of $657.305 to a high of $658.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F9. Represents the weighted average price of the shares sold ranging from a low of $658.30 to a high of $659.24 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F10. Represents the weighted average price of the shares sold ranging from a low of $659.31 to a high of $660.275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F11. Represents the weighted average price of the shares sold ranging from a low of $660.59 to a high of $661.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F12. Represents the weighted average price of the shares sold ranging from a low of $661.65 to a high of $662.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F13. Represents the weighted average price of the shares sold ranging from a low of $662.72 to a high of $663.505 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
- F14. Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning February 14, 2018.
- F15. Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did IDEXX (IDXX) report for its CEO?
What stock options did the IDEXX (IDXX) CEO exercise in this Form 4?
Were the IDEXX (IDXX) CEO’s transactions open-market buys or option exercises?
AI-generated analysis. How Rhea-AI works. Not financial advice.